Kisspeptin, a promising biomarker for miscarriage in early pregnancy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

1. Kisspeptin levels in infertile and miscarried women: a cross-sectional study on the relationship with methylenetetrahydrofolate reductase gene polymorphisms and biochemical parameters.Revista da Associacao Medica Brasileira (1992) · 2025
   Article
2. Advances in clinical applications of kisspeptin-GnRH pathway in female reproduction.Reproductive biology and endocrinology : RB&E · 2022
   Review

Corrections and comments

• Comment on
  Performance of plasma kisspeptin as a biomarker for miscarriage improves with gestational age during the first trimester.2021

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as